EBNA1 may prolong G(2)/M phase and sensitize HER2/neu-overexpressing ovarian cancer cells to both topoisomerase II-targeting and paclitaxel drugs. [electronic resource]
Producer: 20030904Description: 653-9 p. digitalISSN:- 0006-291X
- Antigens, Neoplasm
- Antineoplastic Agents -- therapeutic use
- Apoptosis
- Carcinoma -- drug therapy
- DNA Topoisomerases, Type II
- DNA-Binding Proteins
- Down-Regulation
- Doxorubicin -- therapeutic use
- Drug Delivery Systems
- Drug Therapy, Combination
- Epstein-Barr Virus Nuclear Antigens -- genetics
- Etoposide -- therapeutic use
- Female
- G2 Phase
- Genetic Therapy
- Humans
- Kinetics
- Mitosis
- Ovarian Neoplasms -- drug therapy
- Paclitaxel -- therapeutic use
- Receptor, ErbB-2 -- metabolism
- Topoisomerase II Inhibitors
- Tumor Cells, Cultured
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.